Skip to content

Therapeutic effect of local injection of super-activated platelet lysate on postherpetic neuralgia

Therapeutic effect of local injection of super-activated platelet lysate on postherpetic neuralgia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200063100
Enrollment
Unknown
Registered
2022-08-30
Start date
2022-09-01
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postherpetic neuralgia

Interventions

Group 1 :2 ml of anti-inflammatory and analgesic liquid was injected around each nerve root, and the drug formula was 2% lidocaine 5 ml + 0.9% saline 14 ml + betamethasone 1 ml. Injection once every 7
Group 2:SPL 2 ml was injected around each nerve root, once every 7 days, 3 times as a course of treatment.

Sponsors

The Fourth Affiliated Hospital of Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of PHN: have a history of acute herpes zoster, the pain lasts for more than 1 month, the distribution area of ??the affected nerve is in the innervation area of ??the T1-T12 spinal nerve, there is severe paroxysmal pain, and the nature of the pain is like burning, acupuncture, grab sample, knife cut sample, electric shock sample, etc.; 2. Oral analgesics including pregabalin, tramadol hydrochloride, etc., those who are not well treated by conservative treatment such as physiotherapy; 3. Visual analogue scale (VAS) score >= 6; 4. Volunteer to participate in this study, and have signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Combined with serious medical diseases, such as cardiopulmonary disease or abnormal liver and kidney function; 2. Severe coagulation abnormalities; 3. Infection, ulceration, tumor, etc. at the puncture site; 4. Suffering from severe mental illness and cognitive impairment.

Design outcomes

Primary

MeasureTime frame
short form McGill pain questionnaire;

Secondary

MeasureTime frame
self-rating depression scale, SDS;

Countries

China

Contacts

Public ContactHuacheng Zhou

The Fourth Affiliated Hospital of Harbin Medical University

zhouhuacheng@163.com+86 13936184872

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026